Additionally, this drug is able to inhibit the AR-V7 splice variants and so it seems to be active also in patients refractory to new anti-androgen inhibition [79]. Thus, a phase I study is evaluating its safety in patients with metastatic advanced prostate cancer (NCT02566772). Other AR ...